GlassScriptPhysician profile
Karolyn Miner
NPI 1447997481
$6,432.37
in general payments reported to CMS, 2019-2025
49 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,409 · 2023: $1,609 · 2024: $2,052 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,882 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,881.76 |
| Education | $141.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $435.24 | 2023-2025 | |
| Janssen Biotech, INC. | $430.61 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $418.61 | 2022-2025 | Enhertu, Calquence, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $347.98 | 2022-2025 | Ninlaro, Hyqvia, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $343.89 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $298.31 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Celgene Corporation | $285.88 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Seagen INC. | $285.43 | 2022-2023 | Adcetris, Padcev |
| Amgen INC. | $270.17 | 2022-2023 | Kyprolis, Lumakras, Blincyto |
| Incyte Corporation | $255.47 | 2022-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $250.16 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Adc Therapeutics America, INC. | $200.03 | 2022-2025 | |
| Sobi, INC | $193.87 | 2024-2025 | |
| Eisai INC. | $165.29 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $161.53 | 2022-2025 | Xpovio |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $157.32 | 2022-2025 | |
| Beigene USA, INC. | $137.65 | 2022-2023 | Brukinsa |
| Genentech USA, INC. | $136.51 | 2024-2025 | Polivy, Tecentriq, Columvi |
| Abbvie INC. | $123.01 | 2024-2025 | |
| Astellas Pharma US INC | $121.14 | 2024-2025 | Vyloy, Xospata |
| Lilly USA, LLC | $120.97 | 2022-2024 | Verzenio |
| Pfizer INC. | $110.39 | 2023-2025 | |
| Pharmaessentia USA Corporation | $99.91 | 2022-2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $83.95 | 2022-2024 | Fotivda |
| Array Biopharma INC | $81.01 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $79.94 | 2024-2025 | Opdivo, Opdualag |
| Myriad Genetic Laboratories, INC. | $76.66 | 2022-2023 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $73.24 | 2022 | |
| Glaxosmithkline, LLC. | $69.32 | 2023-2024 | Ojjaara, Shingrix |
| Blueprint Medicines Corporation | $58.04 | 2023-2024 | Ayvakit |
| Mirati Therapeutics, INC. | $52.36 | 2023-2024 | Krazati |
| Geron Corporation | $50.20 | 2024-2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $44.31 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $44.07 | 2022-2024 | |
| Emd Serono, INC. | $43.59 | 2023-2024 | Bavencio |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Stemline Therapeutics INC. | $40.07 | 2023 | Orserdu |
| Gilead Sciences, INC. | $36.34 | 2023 | Trodelvy |
| Morphosys, US INC. | $28.51 | 2022-2023 | Monjuvi |
| Exelixis INC. | $22.21 | 2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $20.80 | 2023 | Imbruvica |
| Organon LLC | $20.68 | 2023 | Ontruzant |
| Regeneron Healthcare Solutions, INC. | $19.31 | 2024 | Libtayo |
| Genmab U.S., INC. | $17.90 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.84 | 2022 | |
| Daiichi Sankyo INC. | $15.40 | 2025 | Enhertu |
| Sun Pharmaceutical Industries INC. | $15.23 | 2025 | |
| Taiho Oncology, INC. | $15.22 | 2025 | |
| Sumitomo Pharma America, INC. | $14.81 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karolyn Miner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.